The Effects of Patent Extension and Take-Back Regulation on Green Pharmacy

References

• Alev I, Atasu A, Toktay LB, Zhang C (2021) Extended producer responsibility for pharmaceuticals. Manufacturing Service Oper. Management, ePub ahead of print March 18, https://doi.org/10.1287/msom.2020.0962.Link, Google Scholar
• American Chemical Society (2015) Examples of green chemistry. Accessed June 17, 2021, http://www.acs.org/content/acs/en/greenchemistry/what-is-green-chemistry/examples.html.Google Scholar
• Anastas PT, Warner JC (1998) Green Chemistry Theory and Practice (Oxford University Press, New York).Google Scholar
• Anastas PT, Boethling R, Voutchkova-Kostal A (2014) Green Processes: Designing Safer Chemicals (Wiley, New York).Google Scholar
• Atasu A, Subramanian R (2012) Extended producer responsibility for e-waste: Individual or collective producer responsibility? Production Oper. Management 21(6):1042–1059.Crossref, Google Scholar
• Atasu A, Özdemir Ö, Van Wassenhove LN (2013) Stakeholder perspectives on e-waste take-back legislation. Production Oper. Management 22(2):382–396.Crossref, Google Scholar
• Basu A, Domb AJ (2018) Recent advances in polyanhydride based biomaterials. Advanced Materials 30(41):1706815.Crossref, Google Scholar
• Baumol WJ (1972) On taxation and the control of externalities. Amer. Econom. Rev. 62(3):307–322.Google Scholar
• Bottazzi G, Dosi G, Lippi M, Pammolli F, Riccaboni M (2001) Innovation and corporate growth in the evolution of the drug industry. Internat. J. Indust. Organ. 19(7):1161–1187.Crossref, Google Scholar
• Bound JP, Voulvoulis N (2005) Household disposal of pharmaceuticals as a pathway for aquatic contamination in the United Kingdom. Environ. Health Perspect. 113(12):1705–1711.Crossref, Google Scholar
• Burrows P (1979) Pigovian taxes, polluter subsidies, regulation, and the size of a polluting industry. Canadian J. Econom. 12(3):494–501.Crossref, Google Scholar
• Calcott P, Walls M (2000) Can downstream waste disposal policies encourage upstream “design for environment”? Amer. Econom. Rev. 90(2):233–237.Crossref, Google Scholar
• Clark JH, Breeden SW, Summerton L (2010) Green(er) pharmacy. Kümmerer K, Hempel M, eds. Green and Sustainable Pharmacy (Springer, Berlin), 37–59.Crossref, Google Scholar
• CMS (2019) NHE (national health expenditure) fact sheet. Accessed June 17, 2021, https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NHE-Fact-Sheet.Google Scholar
• CMS (2020) National health expenditure projections 2019–28. Accessed June 17, 2021, https://www.cms.gov/files/document/national-health-expenditure-projections-2019-28.pdf.Google Scholar
• CVS Health (2017) Public opinion of prescription drug abuse and disposal. Accessed June 17, 2021, https://cvshealth.com/sites/default/files/cvs-health-prescription-drug-abuse-and-disposal-report.pdf.Google Scholar
• Daughton CG (2001) Pharmaceuticals and personal care products in the environment: overarching issues and overview. Daughton CG, Jones-Lepp T, eds. Pharmaceuticals and Personal Care Products in the Environment: Scientific and Regulatory Issues (American Chemical Society, Washington, DC), 2–38.Crossref, Google Scholar
• Daughton CG (2003a) Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy. Environ. Health Perspect. 111(5):757–774.Crossref, Google Scholar
• Daughton CG (2003b) Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. II. Drug disposal, waste reduction, and future directions. Environ. Health Perspect. 111(5):775–785.Crossref, Google Scholar
• Denoth A, Pinget C, Wasserfallen JB (2011) Citizens’ preferences for brand name drugs for treating acute and chronic conditions: A pilot study. Appl. Health Econom. Health Policy 9(2):81–87.Crossref, Google Scholar
• EEA (2010) Pharmaceuticals in the environment: Results of an EEA workshop. Technical report 1, EEA, Copenhagen.Google Scholar
• Esenduran G, Kemahlıoğlu‐Ziya E (2015) A comparison of product take-back compliance schemes. Production Oper. Management 24(1):71–88.Crossref, Google Scholar
• FDA (2017) Disposal of unused medicines: What you should know. Accessed June 17, 2021, https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm101653.htm.Google Scholar
• Gilbert R, Shapiro C (1990) Optimal patent length and breadth. RAND J. Econom. 21(1):106–112.Crossref, Google Scholar
• Gottlieb E (2015) 4 reasons why EPR is the best solution for safe drug disposal, PSI Blog (March 26). Accessed June 17, 2021, https://productstewardshipinstitute.wordpress.com/2015/03/26/4-reasons-why-epr-is-the-best-solution-for-safe-drug-disposal/.Google Scholar
• Grabowski HG, Vernon JM (1992) Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. J. Law Econom. 35(2):331–350.Crossref, Google Scholar
• Grasso C, Buller C, Chapman A, Dale E, Perry W, Stitzhal D (2009) Secure medicine return in Washington State, the PH:ARM pilot. Accessed June 17, 2021, https://www.hazwastehelp.org/HHW/documents/Dec09PHARMReportFINAL.pdf.Google Scholar
• Gui L, Atasu A, Ergun Ö, Toktay LB (2013) Implementing extended producer responsibility legislation. J. Indust. Ecology 17(2):262–276.Crossref, Google Scholar
• Gupta H, Kumar S, Roy SK, Gaud R (2010) Patent protection strategies. J. Pharmacy Bioallied Sci. 2(1):2–7.Crossref, Google Scholar
• Harris BL, Stergachis A, Ried LD (1990) The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Medical Care 28(10):907–917.Crossref, Google Scholar
• Hurwitz MA, Caves RE (1988) Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals. J. Law Econom. 31(2):299–320.Crossref, Google Scholar
• International Pharmaceutical Federation (2015) Green pharmacy practice: Taking responsibility for the environmental impact of medicines. Accessed June 17, 2021, https://fip.org/files/fip/publications/2015-12-Green-Pharmacy-Practice.pdf.Google Scholar
• Jaffe AB (2000) The US patent system in transition: policy innovation and the innovation process. Res. Policy 29(4):531–557.Crossref, Google Scholar
• Kidd KA, Blanchfield PJ, Mills KH, Palace VP, Evans RE, Lazorchak JM, Flick RW (2007) Collapse of a fish population after exposure to a synthetic estrogen. Proc. Natl. Acad. Sci. USA 104(21):8897–8901.Crossref, Google Scholar
• Kitch EW (1977) The nature and function of the patent system. J. Law Econom. 20(2):265–290.Crossref, Google Scholar
• Kjoenniksen I, Lindbaek M, Granas AG (2006) Patients’ attitudes toward and experiences of generic drug substitution in Norway. Pharmacy World Sci. 28(5):284–289.Crossref, Google Scholar
• Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, Barber LB, Buxton HT (2002) Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams, 1999–2000: A national reconnaissance. Environ. Sci. Tech. 36(6):1202–1211.Crossref, Google Scholar
• Kotchen M, Kallaos J, Wheeler K, Wong C, Zahller M (2009) Pharmaceuticals in wastewater: Behavior, preferences, and willingness to pay for a disposal program. J. Environ. Management 90(3):1476–1482.Crossref, Google Scholar
• Krass D, Nedorezov T, Ovchinnikov A (2013) Environmental taxes and the choice of green technology. Production Oper. Management 22(5):1035–1055.Crossref, Google Scholar
• Kroes J, Subramanian R, Subramanyam R (2012) Operational compliance levers, environmental performance, and firm performance under cap and trade regulation. Manufacturing Service Oper. Management 14(2):186–201.Link, Google Scholar
• Lavers RJ (1989) Prescription charges, the demand for prescriptions and morbidity. Appl. Econom. 21(8):1043–1052.Google Scholar
• Lee J (2003) Innovation and strategic divergence: An empirical study of the US pharmaceutical industry from 1920 to 1960. Management Sci. 49(2):143–159.Link, Google Scholar
• Lubick N (2008) Opening the” green pharmacy. Environ. Sci. Tech. 42(23):8620–8621.Crossref, Google Scholar
• Merges RP (1988) Commercial success and patent standards: Economic perspectives on innovation. California Law Rev. 76(4):803–876.Crossref, Google Scholar
• Moorthy KS (1984) Market segmentation, self-selection, and product line design. Marketing Sci. 3(4):288–307.Link, Google Scholar
• Nault BR (1996) Equivalence of taxes and subsidies in the control of production externalities. Management Sci. 42(3):307–320.Link, Google Scholar
• NCSL (2017) State prescription drug return, reuse and recycling laws. Accessed June 17, 2021, http://www.ncsl.org/research/health/state-prescription-drug-return-reuse-and-recycling.aspx.Google Scholar
• Oaks JL, Gilbert M, Virani MZ, Watson RT, Meteyer CU, Rideout BA, Shivaprasad H, et al. (2004) Diclofenac residues as the cause of vulture population decline in Pakistan. Nature 427(6975):630–633.Crossref, Google Scholar
• O’Brien B (1989) The effect of patient charges on the utilisation of prescription medicines. J. Health Econom. 8(1):109–132.Crossref, Google Scholar
• Palmer K, Walls M (1997) Optimal policies for solid waste disposal taxes, subsidies, and standards. J. Public Econom. 65(2):193–205.Crossref, Google Scholar
• Plambeck E, Wang Q (2009) Effects of e-waste regulation on new product introduction. Management Sci. 55(3):333–347.Link, Google Scholar
• Product Stewardship Institute (2011) Product stewardship financing models: A look at the post-consumer pharmaceutical stewardship association. Accessed June 17, 2021, https://cdn.ymaws.com/www.productstewardship.us/resource/resmgr/imported/PCPSA_financing_3_17_11.pdf.Google Scholar
• Ray S, Boyaci T, Aras N (2005) Optimal prices and trade-in rebates for durable, remanufacturable products. Manufacturing Service Oper. Management 7(3):208–228.Link, Google Scholar
• Ruhoy IS, Daughton CG (2008) Beyond the medicine cabinet: An analysis of where and why medications accumulate. Environ. Internat. 34(8):1157–1169.Crossref, Google Scholar
• Scherer FM, Ross D (1990) Industrial Market Structure and Economic Performance, 3rd ed. (Houghton Mifflin, Boston).Google Scholar
• Shah S (2010) As pharmaceutical use soars, drugs taint water & wildlife. Yale Environment 360. Accessed June 17, 2021, https://e360.yale.edu/features/as_pharmaceutical_use_soars_drugs_taint_water_and_wildlife.Google Scholar
• Smith DG (1993) The effects of copayments and generic substitution on the use and costs of prescription drugs. Inquiry 30(2):189–198.Google Scholar
• The Economist (2017) Pigouvian taxes. (August 19), https://www.economist.com/schools-brief/2017/08/19/pigouvian-taxes.Google Scholar
• Tong AY, Peake BM, Braund R (2011) Disposal practices for unused medications around the world. Environ. Internat. 37(1):292–298.Crossref, Google Scholar
• Trueman P, Taylor D, Lowson K, Bligh A, Meszaros A, Wright D, Glanville J, et al. (2010) Evaluation of the scale, causes and costs of waste medicines. Final report of UK Department of Health national project, University of York, York, UK.Google Scholar
• Vajda AM, Barber LB, Gray JL, Lopez EM, Woodling JD, Norris DO (2008) Reproductive disruption in fish downstream from an estrogenic wastewater effluent. Environ. Sci. Tech. 42(9):3407–3414.Crossref, Google Scholar
• Walls M (2006) Extended producer responsibility and product design: Economic theory and selected case studies. Discussion paper 06-08, Resources for the Future, Washington, DC.Google Scholar
• Wisconsin Department of Natural Resources (DNR) (2012) Wisconsin household pharmaceutical waste collection: Challenges and opportunities. Accessed June 17, 2021, http://dnr.wi.gov/topic/healthwaste/documents/2012householdpharmstudy.pdf.Google Scholar